Associated Genetic Biomarkers
FANCD2 Loss is present in 0.04% of AACR GENIE cases, with breast carcinoma, ampulla of vater carcinoma, ovarian neoplasm, prostate cancer, and renal cell carcinoma having the greatest prevalence .
FANCD2 Loss serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 Loss as an inclusion criterion, 1 is phase 2 (1 open).
Trials with FANCD2 Loss in the inclusion eligibility criteria most commonly target breast carcinoma .
Olaparib is the most frequent therapy in trials with FANCD2 Loss as an inclusion criteria .
Significance of FANCD2 Loss in Diseases
Breast Carcinoma +
FANCD2 is mutated in 2.85% of breast carcinoma patients with FANCD2 Loss present in 0.14% of all breast carcinoma patients .
FANCD2 Loss is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 Loss and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Olaparib is the most frequent therapy in trials for breast carcinoma that contain FANCD2 Loss .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.